Concise Review

Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine

Rebekah M. Samsonraj, Michael Raghunath, Victor Nurcombe, James H. Hui, Andre J van Wijnen, Simon M. Cool

Research output: Contribution to journalReview article

81 Citations (Scopus)

Abstract

Mesenchymal stem cells (MSC) hold great potential for regenerative medicine because of their ability for self-renewal and differentiation into tissue-specific cells such as osteoblasts, chondrocytes, and adipocytes. MSCs orchestrate tissue development, maintenance and repair, and are useful for musculoskeletal regenerative therapies to treat age-related orthopedic degenerative diseases and other clinical conditions. Importantly, MSCs produce secretory factors that play critical roles in tissue repair that support both engraftment and trophic functions (autocrine and paracrine). The development of uniform protocols for both preparation and characterization of MSCs, including standardized functional assays for evaluation of their biological potential, are critical factors contributing to their clinical utility. Quality control and release criteria for MSCs should include cell surface markers, differentiation potential, and other essential cell parameters. For example, cell surface marker profiles (surfactome), bone-forming capacities in ectopic and orthotopic models, as well as cell size and granularity, telomere length, senescence status, trophic factor secretion (secretome), and immunomodulation, should be thoroughly assessed to predict MSC utility for regenerative medicine. We propose that these and other functionalities of MSCs should be characterized prior to use in clinical applications as part of comprehensive and uniform guidelines and release criteria for their clinical-grade production to achieve predictably favorable treatment outcomes for stem cell therapy. Stem Cells Translational Medicine 2017;6:2173–2185.

Original languageEnglish (US)
Pages (from-to)2173-2185
Number of pages13
JournalStem cells translational medicine
Volume6
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Regenerative Medicine
Mesenchymal Stromal Cells
Stem Cells
Translational Medical Research
Immunomodulation
Differentiation Antigens
Telomere
Chondrocytes
Cell- and Tissue-Based Therapy
Osteoblasts
Cell Size
Adipocytes
Quality Control
Orthopedics
Maintenance
Guidelines
Bone and Bones
Therapeutics

Keywords

  • Bone marrow
  • Characterization
  • Mesenchymal stem/stromal cells
  • Regenerative medicine
  • Release criteria

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

Samsonraj, R. M., Raghunath, M., Nurcombe, V., Hui, J. H., van Wijnen, A. J., & Cool, S. M. (2017). Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine. Stem cells translational medicine, 6(12), 2173-2185. https://doi.org/10.1002/sctm.17-0129

Concise Review : Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine. / Samsonraj, Rebekah M.; Raghunath, Michael; Nurcombe, Victor; Hui, James H.; van Wijnen, Andre J; Cool, Simon M.

In: Stem cells translational medicine, Vol. 6, No. 12, 01.12.2017, p. 2173-2185.

Research output: Contribution to journalReview article

Samsonraj, RM, Raghunath, M, Nurcombe, V, Hui, JH, van Wijnen, AJ & Cool, SM 2017, 'Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine', Stem cells translational medicine, vol. 6, no. 12, pp. 2173-2185. https://doi.org/10.1002/sctm.17-0129
Samsonraj, Rebekah M. ; Raghunath, Michael ; Nurcombe, Victor ; Hui, James H. ; van Wijnen, Andre J ; Cool, Simon M. / Concise Review : Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine. In: Stem cells translational medicine. 2017 ; Vol. 6, No. 12. pp. 2173-2185.
@article{32cc345c3b724df58aecb907a574096a,
title = "Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine",
abstract = "Mesenchymal stem cells (MSC) hold great potential for regenerative medicine because of their ability for self-renewal and differentiation into tissue-specific cells such as osteoblasts, chondrocytes, and adipocytes. MSCs orchestrate tissue development, maintenance and repair, and are useful for musculoskeletal regenerative therapies to treat age-related orthopedic degenerative diseases and other clinical conditions. Importantly, MSCs produce secretory factors that play critical roles in tissue repair that support both engraftment and trophic functions (autocrine and paracrine). The development of uniform protocols for both preparation and characterization of MSCs, including standardized functional assays for evaluation of their biological potential, are critical factors contributing to their clinical utility. Quality control and release criteria for MSCs should include cell surface markers, differentiation potential, and other essential cell parameters. For example, cell surface marker profiles (surfactome), bone-forming capacities in ectopic and orthotopic models, as well as cell size and granularity, telomere length, senescence status, trophic factor secretion (secretome), and immunomodulation, should be thoroughly assessed to predict MSC utility for regenerative medicine. We propose that these and other functionalities of MSCs should be characterized prior to use in clinical applications as part of comprehensive and uniform guidelines and release criteria for their clinical-grade production to achieve predictably favorable treatment outcomes for stem cell therapy. Stem Cells Translational Medicine 2017;6:2173–2185.",
keywords = "Bone marrow, Characterization, Mesenchymal stem/stromal cells, Regenerative medicine, Release criteria",
author = "Samsonraj, {Rebekah M.} and Michael Raghunath and Victor Nurcombe and Hui, {James H.} and {van Wijnen}, {Andre J} and Cool, {Simon M.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1002/sctm.17-0129",
language = "English (US)",
volume = "6",
pages = "2173--2185",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "12",

}

TY - JOUR

T1 - Concise Review

T2 - Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine

AU - Samsonraj, Rebekah M.

AU - Raghunath, Michael

AU - Nurcombe, Victor

AU - Hui, James H.

AU - van Wijnen, Andre J

AU - Cool, Simon M.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Mesenchymal stem cells (MSC) hold great potential for regenerative medicine because of their ability for self-renewal and differentiation into tissue-specific cells such as osteoblasts, chondrocytes, and adipocytes. MSCs orchestrate tissue development, maintenance and repair, and are useful for musculoskeletal regenerative therapies to treat age-related orthopedic degenerative diseases and other clinical conditions. Importantly, MSCs produce secretory factors that play critical roles in tissue repair that support both engraftment and trophic functions (autocrine and paracrine). The development of uniform protocols for both preparation and characterization of MSCs, including standardized functional assays for evaluation of their biological potential, are critical factors contributing to their clinical utility. Quality control and release criteria for MSCs should include cell surface markers, differentiation potential, and other essential cell parameters. For example, cell surface marker profiles (surfactome), bone-forming capacities in ectopic and orthotopic models, as well as cell size and granularity, telomere length, senescence status, trophic factor secretion (secretome), and immunomodulation, should be thoroughly assessed to predict MSC utility for regenerative medicine. We propose that these and other functionalities of MSCs should be characterized prior to use in clinical applications as part of comprehensive and uniform guidelines and release criteria for their clinical-grade production to achieve predictably favorable treatment outcomes for stem cell therapy. Stem Cells Translational Medicine 2017;6:2173–2185.

AB - Mesenchymal stem cells (MSC) hold great potential for regenerative medicine because of their ability for self-renewal and differentiation into tissue-specific cells such as osteoblasts, chondrocytes, and adipocytes. MSCs orchestrate tissue development, maintenance and repair, and are useful for musculoskeletal regenerative therapies to treat age-related orthopedic degenerative diseases and other clinical conditions. Importantly, MSCs produce secretory factors that play critical roles in tissue repair that support both engraftment and trophic functions (autocrine and paracrine). The development of uniform protocols for both preparation and characterization of MSCs, including standardized functional assays for evaluation of their biological potential, are critical factors contributing to their clinical utility. Quality control and release criteria for MSCs should include cell surface markers, differentiation potential, and other essential cell parameters. For example, cell surface marker profiles (surfactome), bone-forming capacities in ectopic and orthotopic models, as well as cell size and granularity, telomere length, senescence status, trophic factor secretion (secretome), and immunomodulation, should be thoroughly assessed to predict MSC utility for regenerative medicine. We propose that these and other functionalities of MSCs should be characterized prior to use in clinical applications as part of comprehensive and uniform guidelines and release criteria for their clinical-grade production to achieve predictably favorable treatment outcomes for stem cell therapy. Stem Cells Translational Medicine 2017;6:2173–2185.

KW - Bone marrow

KW - Characterization

KW - Mesenchymal stem/stromal cells

KW - Regenerative medicine

KW - Release criteria

UR - http://www.scopus.com/inward/record.url?scp=85035065066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035065066&partnerID=8YFLogxK

U2 - 10.1002/sctm.17-0129

DO - 10.1002/sctm.17-0129

M3 - Review article

VL - 6

SP - 2173

EP - 2185

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 12

ER -